Streptococcus suis is an emerging zoonotic agent of septicemia and meningitis. Knowledge on host immune responses toward S. suis and strategies used by this pathogen for subversion of these responses is scarce. Here, S. suis modulation of dendritic cell (DC) functions were assessed for the first time. Using S. suis knockout mutants in capsular polysaccharide (CPS) expression, it was shown that CPS blocks DC phagocytosis and impairs cytokine release by hindering cell wall components. Mutants impaired in D-alanylation of lipoteichoic acid (LTA) or N-deacetylation of peptidoglycan (PG) further demonstrated the importance of cell wall in modulation of DC activation. Notably, LTA/PG modifications were identified as major players in resistance to complement-dependent killing by DCs. Finally, S. suis hemolysin was partially involved in cytokine release and also contributed to bacterial escape of opsonophagocytosis. Overall, S. suis uses its arsenal of virulence factors to modulate DC functions and escape immune surveillance.
Streptococcus suis is an emerging zoonotic agent of septicemia and meningitis. Knowledge on host immune responses toward S. suis and strategies used by this pathogen for subversion of these responses is scarce. Here, S. suis modulation of dendritic cell (DC) functions were assessed for the first time. Using S. suis knockout mutants in capsular polysaccharide (CPS) expression, it was shown that CPS blocks DC phagocytosis and impairs cytokine release by hindering cell wall components. Mutants impaired in D-alanylation of lipoteichoic acid (LTA) or N-deacetylation of peptidoglycan (PG) further demonstrated the importance of cell wall in modulation of DC activation. Notably, LTA/PG modifications were identified as major players in resistance to complement-dependent killing by DCs. Finally, S. suis hemolysin was partially involved in cytokine release and also contributed to bacterial escape of opsonophagocytosis. Overall, S. suis uses its arsenal of virulence factors to modulate DC functions and escape immune surveillance.
Streptococcus suis serotype 2 is a major swine pathogen mainly associated with meningitis and septicemia [1, 2] . Until recently, S. suis disease in humans was considered rare, mostly affecting people in contact with swine or pork by-products. However, S. suis is now emerging as an important threat to human health, especially in Asia. S. suis is identified as the leading cause of adult meningitis in Vietnam, the second in Thailand, and the third in Hong Kong. In 2005, an important outbreak in China resulted in more than 200 human cases with a 20% fatality rate. Patients presented with symptoms associated with streptococcal toxic shock-like syndrome, including hemorrhage and coma [1] .
S. suis pathogenesis of infection is poorly understood, and attempts to control the infection are hampered by lack of effective vaccines. Notably, low specific antibody production is generated during S. suis infection [3] . However, mechanisms involved in innate and adaptive immune responses toward S. suis remain essentially unknown. Increased severity of S. suis infections in humans underscores the critical need to better understand the interactions between S. suis and the immune system to generate an effective immune response against this pathogen.
Several virulence factors have been proposed. The capsular polysaccharide (CPS) is considered a critical antiphagocytic factor [2, 4, 5] . The serotype 2 CPS structure was recently described [6] and is composed of 5 different sugars, including sialic acid. Among several proteins [7] , a hemolysin, suilysin, has been characterized as a cholesterol-binding cytolysin [7, 8] . Suilysin is involved in modulation of S. suis interactions with different host cells [2, 7] . Modifications of cell wall (CW) components such as the N-deacetylation of peptidoglycan (PG) and the D-alanylation of lipoteichoic acid (LTA) also contribute to S. suis virulence, as demonstrated in mouse and pig models of infection [9, 10] . Because CPS, CW modifications, and suilysin seem to be involved in the virulence of S. suis, particularly by impairing critical steps in antigen processing such as phagocytosis and killing, we chose to study their role in modulation of dendritic cell (DC) functions.
DCs are powerful antigen-presenting cells that capture and process antigens, undergo a maturation process characterized by cytokine production and upregulation of costimulatory molecules, and finally migrate to adjacent lymphoid organs to activate T cells [11] . DCs are key elements in induction of innate immunity against pathogens and are crucial for T-cell priming and initiation of adaptive responses. Consequently, interactions between DCs and pathogens can strongly influence disease outcome.
Previously, we demonstrated that the mouse model of infection is a valid model to reproduce S. suis infection [12] . In this study, we used mouse bone marrow-derived DCs (bmDCs) to investigate the capacity of S. suis to interact with DCs and to induce their maturation and activation. We also examined the contribution of known virulence factors on these interactions.
MATERIALS AND METHODS

Bacterial Strains, Plasmids, and Growth Conditions
Bacterial strains and plasmids used are listed in Table 1 . S. suis strains were grown as previously described [4] and diluted in complete cell culture medium before experiments. The number of colony-forming units (CFU)/mL in the final suspension was determined using Autoplate 4000 (Spiral Biotech).
Construction of the DcpsF Mutant
A nonencapsulated mutant was constructed in wild-type strain P1/7 by precise, in-frame deletion of the cpsF/SSU_0520 gene using splicing-by-overlap-extension polymerase chain reaction (PCR) [21] . The DcpsF deletion allele was cloned into plasmid pCR2.1 (Invitrogen), extracted with BamHI and PstI and recloned into thermosensitive Escherichia coli-S. suis shuttle plasmid pSET4s [22] . E. coli transformation was performed as reported previously [23] . Procedures for S. suis electroporation and DcpsF mutant isolation were previously described [22] . Allelic replacement was confirmed by PCR and sequencing analysis with a 310 Genetic Analyzer (Applied Biosystems). The nonencapsulated phenotype was confirmed by transmission electron microscopy (TEM) using polycationic ferritin labeling, as reported [24] .
BmDC Generation
Female C57BL/6 mice (Charles River Laboratories) were used to generate bmDCs, as described previously [25] . Experiments were conducted in accordance with the University of Montreal Animal Welfare Committee guidelines and policies. In brief, bone marrow cells were cultured in RPMI 1640 medium supplemented with 5% heat-inactivated fetal bovine serum, 10 mM HEPES, 2 mM L-glutamine, and 50 lM 2-mercaptoethanol (Gibco). Complete medium was complemented with 20% granulocyte Strain P1/7 is a virulent S. suis serotype 2 strain whose genome was recently sequenced [20] .
DdltA, DpgdA, and Dsly mutants present a normal morphology and are as encapsulated as the wild-type strain [9, 10] .
DdltA, DpgdA, DcpsF, and B218 mutants present the same hemolytic activity due to the release of suilysin as the wild-type strain (data not shown).
macrophage-colony stimulating factor from mouse-transfected Ag8653 cells [25] . On day 8, after a subculture step, cells were collected and used as immature bmDCs. Cell purity was 85%-88% CD11c 1 cells, as reported previously [25] . For confirmation, bmDCs were further purified to .95% purity by positive selection using anti-CD11c microbeads (Miltenyi Biotec) [26] .
Bactericidal Assay
Bacteria were either not opsonized or were opsonized using 20% of either heat-inactivated normal mouse serum or complete normal mouse serum in phosphate-buffered saline for 30 minutes at 37°C with shaking. BmDCs (2 3 10 6 cells/mL) were mixed with different S. suis strains (2 3 10 4 CFU/mL) in microtubes and incubated for 6 hours at 37°C with 5% CO 2 . Assay conditions were chosen based on the kinetics of S. suis killing by bmDCs (data not shown). After incubation, cells were lysed and viable bacterial counts performed. Tubes with bacteria alone were treated similarly and used as controls.
BmDC Stimulation Assay
BmDCs were stimulated with 1 lM CpG (ODN 1826, InvivoGen) as positive control, or S. suis strains (10 6 CFU/mL; initial infection ratio of 1:1). In selected experiments, bacterial strains were opsonized as described above. At different times after infection, supernatants were collected for cytokine quantification by sandwich enzyme-linked immunosorbent assay using pair-matched antibodies from R&D Systems or eBioscience. Cells were analyzed for costimulatory molecule expression by fluorescence activated cell sorting (FACS). The lactate dehydrogenase (LDH) assay was used to measure cytotoxicity levels (CytoTox96, Promega) as described [5] . Final assay conditions were selected based on kinetics studies and absence of cytotoxicity (data not shown). 
Confocal and Electron Microscopy
For confocal analysis, after 2 hours of bacteria-cell contact, cells were washed and fixed with methanol/acetone (80:20) for 20 minutes at 220°C, blocked, and incubated for 1 hour with rabbit anti-S. suis serum and rat anti-LAMP1 antibody (Developmental Studies Hybridoma Bank). Coverslips were then incubated with Alexa Fluor 488 goat antirabbit immunoglobulin G (IgG) and Alexa Fluor 568 goat antirat IgG (Invitrogen) for 30 minutes and mounted on glass slides with moviol containing DABCO and DAPI. Immunofluorescence studies were also performed to determine levels of complement deposition on bacteria. Either a bovine serum albumin solution or complete normal mouse serum was added for 30 minutes at 37°C to a 10 6 bacterial suspension. In some cases, serum was pretreated with purified suilysin for 30 minutes at 37°C before opsonization. Bacteria were then washed and incubated with goat IgG fraction to mouse complement C3 (MP Biomedicals) for 1 hour, followed by Alexa Fluor 488 mouse antigoat IgG for 30 minutes. Samples were analyzed with a FV-1000 confocal microscope and Fluoview software. For TEM and scanning electron microscopy, bmDCs incubated with S. suis for 4 hours were washed, fixed, and processed as reported previously [27] .
Statistical Analysis
Data are expressed as mean 6 SEM and were analyzed for significance using unpaired Student t test. A P value , .05 was used as a threshold for significance. Experiments were repeated at least 3 times.
RESULTS
CW Modifications and Suilysin Are Important for S. suis Resistance to Killing by bmDCs
First, we confirmed that all mutant strains present similar growth curves as their respective wild-type parental strains ( Figure 1A ). As shown in Figure 1B , the wild-type strains were highly resistant to killing, and the presence of serum slightly, but not significantly, increased killing levels. Conversely, both nonencapsulated mutant strains were largely destroyed in all conditions tested. Thus, killing of nonencapsulated strains is not strictly dependent on serum factors. In contrast, the DdltA, DpgdA, and Dsly strains were all resistant to killing in the absence of opsonization or after opsonization with heat-inactivated serum but were significantly more susceptible to killing following complete serum opsonization.
Impairment of Complement Deposition by CW Modifications, Suilysin, and CPS
C3 deposition on streptococci was examined by immunofluorescence ( Figure 1C ). Wild-type streptococci showed almost complete absence of C3 deposition, whereas increased labeling was observed on nonencapsulated strain surface. The DdltA and DpgdA strains showed bright cell contour labeling, indicating high levels of C3 deposition. Because suilysin is a secreted toxin, its role in C3 deposition cannot be analyzed with washed bacteria. To overcome this constraint, we pretreated complete normal serum with increasing doses of purified suilysin. Suilysin-treated serum was then used to opsonize the DdltA mutant strain, which should report high levels of C3 deposition. Using this system, we observed that suilysin pretreatment of serum resulted in markedly reduced levels of C3 deposition on DdltA bacteria.
Encapsulated Wild-type S. suis Escapes Internalization by DCs
Confocal microscopy was performed using serum against S. suis and an antibody against LAMP1 (lysosomal-associated membrane protein 1) (Figure 2A ). Under nonopsonic conditions, few internalized bacteria were noticeable for the wildtype strain 31533 and the mutants Dsly, DdltA, and DpgdA. When these strains were opsonized with complete serum, internalization by bmDCs showed a minor increase for wild-type 31533 strain. This increase was more marked for DdltA, DpgdA, Figure 1 . A, Growth curves of Streptococcus suis wild-type P1/ 7 and its nonencapsulated mutant strain (left). Growth curves of S. suis wild-type 31533 and mutant strains (right). B, Effect of serum on the capacity of bone marrow-derived dendritic cells (bmDCs) to kill different S. suis strains. Bacteria were either nonopsonized or preopsonized with 20% complete serum or 20% heat-inactivated serum for 30 minutes prior to incubation with bmDCs for 6 hours. Data are expressed as mean percentage (6 SEM) of killed bacteria. * P ,.05 indicates statistically significant differences between nonopsonized strains and their respective serum-opsonized counterparts. # P , .05 denotes significant differences between values obtained with serum-opsonized bacteria vs those obtained with heat-inactivated serum. C, Confocal microscopy showing complement deposition on S. suis. The wild-type 31533 strain, the nonencapsulated B218 mutant, the DdltA strain, or the DpgdA strain was preopsonized with complete serum and then incubated with an antibody against mouse complement component C3 to observe complement deposition. To assess the role of suilysin in complement deposition, complete serum was pretreated with 0.2 lg/mL of purified suilysin. Suilysin-treated serum was then used for opsonization of the DdltA strain. Original magnification 1503. Scale bar, 4 lM (scale bar applies to all panels). CPS, capsular polysaccharide; CW, cell wall; n.d., not done; OD, optical density; Sly, suilysin. Figure 2 . A, Confocal microscopy showing internalization of Streptococcus suis. Bone marrow-derived dendritic cells (bmDCs) were incubated with the wildtype strain 31533, the nonencapsulated mutant B218, the DdltA strain, the DpgdA strain, or the Dsly strain, not opsonized (top panels) or preopsonized with complete serum (middle panels) or heat-inactivated serum (lower panels). After a bacteria-cell contact of 2 hours, cells were fixed and labeled with serum against S. suis (Alexa Fluor 488, green) and an antibody specific for LAMP1 (Alexa Fluor 568, red). DAPI was used to stain the nuclei (blue). Original magnification 603. Scale bar, 10 lM (scale bar applies to all panels). B, Scanning electron micrographs showing interactions between bmDCs and S. suis (10 and Dsly mutants (Figure 2A, middle panels) . Opsonization with heat-inactivated serum partially restored internalization levels to those observed under nonopsonic conditions (Figure 2A , lower panels). In contrast, the nonencapsulated mutant was highly internalized by bmDCs under all conditions tested. This is in agreement with bactericidal test results.
SEM showed that S. suis interacts with bmDCs. Cocci were found associated to the cell surface both for the wild-type strain and its nonencapsulated mutant ( Figure 2B ). The CPS might impair S. suis interactions with bmDCs because the nonencapsulated strain seemed to adhere more than the wild type to DCs. Compared to the high numbers of streptococci observed intracellularly with the nonencapsulated mutant, TEM analysis showed that few bmDCs contained wild-type strain 31533 cocci despite serum opsonization ( Figure 2C , II and III). In agreement with aforementioned data, bmDCs incubated with the opsonized DdltA, DpgdA, or Dsly strain showed more bacteria internalized than the wild-type strain ( Figure 2C , IV-VI).
S. suis Virulence Factors Regulate bmDC Release of Several Cytokines
S. suis stimulation of bmDCs resulted in time-dependent cytokine release (data not shown). At 16 hours after stimulation, S. suis wild-type strain-stimulated bmDCs produced significant amounts of interleukin (IL)-1b, IL-6, tumor necrosis factor (TNF)-a, IL-12p70, IL-23, IL-10, CXCL1, CCL2, CXCL9, and CXCL10 ( Figure 3) . Nonencapsulated mutants induced significantly higher levels of all cytokines, except for IL-1b and CCL2 ( Figure 3C-J) . The DdltA and DpgdA mutants induced reduced levels of IL-10, IL-12p70, and CXCL10 ( Figure 3D-H) , while the Dsly mutant induced lower levels of IL-12p70 and IL-10 ( Figure 3D and E). Main cytokine results were confirmed with bmDCs purified by magnetic cell sorting (data not shown).
Serum Modulates Cytokine Release by S. suis-Activated bmDCs
Serum opsonization was shown to significantly modify IL-12p70 and IL-10 production by bmDCs (Figure 4) . For the DdltA, DpgdA, and Dsly mutants, the complement cascade seems to be involved, at least in part, in the observed downregulation of IL-10 production because bmDC stimulation with these mutants opsonized with heat-inactivated serum significantly reduced its effect. In the case of IL-12p70, when these S. suis mutant strains were opsonized with heat-inactivated serum, there was a tendency, albeit not significant, to return to normal levels of this cytokine production. Thus, the involvement of other serum components in modulation of cytokine production cannot be excluded. Serum opsonization of the nonencapsulated mutant had no visible effect on cytokine production.
S. suis Induces bmDC Expression of Maturation Markers
The ability of S. suis to increase expression of CD40, CD54, CD80, CD86, and MHC class II (MHC-II) on bmDCs was analyzed. No significant changes in CD54 and CD80 expression were observed (data not shown). However, as shown in Figure 5 , S. suis-stimulated bmDCs showed higher expression of CD40. Two well-segregated subpopulations, a CD86 high and MHC-II high subset and a CD86 low and MHC-II low subset, were observed among the CD11c1 bmDCs population, as reported previously [25] . S. suis stimulation resulted in higher percentages of CD86 high and MHC-II high subpopulations compared with control cells. No differences were observed between the wild-type strain and the mutants ( Figure 5 , gray-filled histograms). Only a slight decrease, albeit reproducible, in the expression of CD40, CD86, and/or MHC-II was discernible when bmDCs were incubated with opsonized S. suis strains ( Figure 5 , black line histograms).
DISCUSSION
Although S. suis is a pathogen of increasing importance for human health, mechanisms leading to an efficient immune response against S. suis are poorly understood. A typical type 1 inflammatory response was observed in an S. suis mouse model of septicemia and meningitis [12] . However, interactions between S. suis and immune mediators have not been characterized. This work describes for the first time the interaction of S. suis with DCs and modulation of their maturation and activation. Effective bacterial killing by DCs is generally assumed to require internalization, which in turn would have an impact on antigen presentation by DCs. However, we showed here that S. suis escapes this immune surveillance. Indeed, under nonopsonic conditions, the CPS is sufficient to protect S. suis from bmDC-mediated killing, confirming the role of CPS as an antiphagocytic factor [4, 5] . Nonetheless, in the presence of serum, as normally occurs during natural infection, S. suis uses an arsenal of virulence factors to resist serum-mediated opsonophagocytosis and killing. Immunofluorescence confirmed that CPS, LTA, and PG modifications as well as suilysin all impair complement deposition on S. suis. Previous studies demonstrated suilysin contribution to S. suis resistance to complement-dependent killing by neutrophils [5, 7] . One hypothesis suggested that the toxin might activate complement and reduce complement availability for bacterial opsonization, as previously shown with pneumolysin, a suilysin-related toxin produced by Streptococcus pneumoniae [28] .
Another major finding is the involvement of CW modifications in resistance to complement-dependent killing. Typically, the CPS is considered the major factor interfering with complement activation, especially for sialic-acid-containing capsules, as is the case with S. suis. Sialylation of CPS is important for group B Streptococcus virulence because it has inhibitory effects on bacterial intracellular killing and acts by impairing complement deposition through sialic aciddependent inhibition of the alternative pathway [29] . This seems not to be the case for S. suis because DdltA, DpgdA, and Dsly mutants failed to resist opsonophagocytosis and killing despite the presence of an intact CPS. Generally, LTA D-alanylation is an important virulence factor for Gram-positive pathogens because it modulates bacterial surface charges, resistance to cationic peptides, and ligand binding [30] . As such, charge compensation by D-alanylation reduces binding of complement component C1q [31] . Recently, LTA D-alanylation was reported as being important for Streptococcus pyogenes resistance to complement. The dltA inactivation in this pathogen leads to increased C3b deposition concomitant with reduced M protein expression [32] . Although no M protein equivalent has been described for S. suis [8] , increased C3b deposition is clearly observed in the S. suis DdltA mutant strain. The mechanism underlying this activity is still unknown. . Sample dilutions giving optical density readings in the linear portion of the enzyme-linked immunosorbent assay standard curves were used to quantify cytokine levels. Data are expressed as mean 6 SEM and were analyzed for significance using unpaired Student t test. Experiments were repeated 4 times with 2 technical replicates. *P , .05 denotes values obtained with the nonencapsulated mutants that are significantly higher from those obtained with their respective wild-type strains. # P , .05 denotes values that are significantly lower than those obtained with the wild-type strain. Detection limits of cytokines: interleukin (IL)-1b, 0.03 ng/mL; IL-6, 0.125 ng/mL; IL-10, 0.0625 ng/mL; IL-12p70, 0.078 ng/mL; IL-23, 0.0625 ng/mL; tumor necrosis factor (TNF)-a, 0.125 ng/mL; CXCL1, 0.05 ng/mL; CXCL9, 0.0625 ng/mL; CXCL10, 0.0625 ng/mL; CCL2, 0.0625 ng/mL.
Aside from dltA, to the best of our knowledge, this is the first time that N-deacetylation of PG is reported as involved in resistance to complement-dependent phagocytosis and killing.
N-deacetylation of PG allows Gram-positive bacteria to circumvent host defenses, mainly by escaping Nod1/2 surveillance and/or increased resistance to lysozyme [33] . A previous study revealed a significant contribution of pgdA to S. suis virulence traits. S. suis DpgdA mutant was shown to be highly attenuated in murine and porcine models of infection, following a severe impairment in its ability to persist in blood and escape neutrophil-mediated clearance [10] . Modifications of PG, such as O-acetylation, were also shown to regulate ligand binding [34, 35] . Experiments are ongoing to further investigate the importance of LTA D-alanylation and PG N-deacetylation in complement-dependent killing.
All S. suis strains triggered bmDC maturation, as shown by increased CD40, CD86, and MHC-II expression. No specific role could be attributed to any of the virulence factors tested because all strains induced equally the expression of costimulatory molecules by DCs. However, the strains tested differentially modulated the release of proinflammatory, Th1 driving and regulatory cytokines. In addition, high levels of the chemokines CXCL1, CXCL10, and CCL2 and low, albeit significant, levels of CXCL9 were observed. This is the first report on CXCL9, CXCL10, and IL-23 production following S. suis cell stimulation. CXCL9 and CXCL10 are involved in T-and NK-cell recruitment, while IL-23 is particularly efficient in supporting inteferon-c production and memory T-cell proliferation [36, 37] . CPS interfered with the release of several cytokines but failed to modulate CCL2 and IL-1b production. Previous studies showed that S. suis CPS is required for optimal CCL2 production by human monocytes, brain endothelial cells, and blood leukocytes [14, 19, 38] . Increased exposure of CW components due to absence of CPS may account for higher capacity of nonencapsulated mutants to induce most cytokine secretion and confirm the role of CW components as major cytokine modulators [14, 38, 39] . This is supported by the fact that IL-12p70, IL-10, and CXCL10 release was diminished following bmDC stimulation by the CW mutants. Similarly, a Streptococcus gordonii mutant strain defective for LTA D-alanylation induced reduced IL-12p70, IL-10, IL-6, and TNF-a levels [40] . Bacteria-derived LTA and PG have already been shown to be responsible for the release of CXCL10 by different cell types [41, 42] . In addition to CW components, several microbial toxins can also modulate inflammatory pathways [43] . In previous work with brain endothelial cells, S. suis suilysin was shown to contribute to IL-6 and IL-8 production [19] . In our model, suilysin seems to significantly contribute to the release of the immunomodulatory cytokines IL-12p70 and IL-10. To date, the mechanism by which suilysin induces cytokine release remains unknown. S. pneumoniae pneumolysin recognizes Toll-like receptor (TLR) 4 on DCs [43] . However, previous in vivo studies carried out in our laboratory indicate a strong TLR2 and CD14, but not TLR4, activation in the brains of mice infected with the suilysin-positive S. suis strain 31533 [12] . Similar results were obtained in vitro with human monocytes [38] .
S. suis opsonization with complete serum was found to downregulate IL-12 and upregulate IL-10 release. This modulation seems to be independent of S. suis uptake and killing levels by bmDCs since it is also noticeable with the wild-type strain, the susceptibility of which to phagocytosis/killing is only slightly increased in the presence of complete serum. S. suis activation of cytokine release by phagocytes has been reported as a phagocytosis-independent event [44, 45] . We might hypothesize that increased ligation of receptors specific for serum factors might account for modulation of IL-12/IL-10 production ratio after DC activation with serum-opsonized bacteria. Since the nonencapsulated mutant is highly adherent to DCs (Figure 2) , the effect of serum factors is not noticeable for this strain. LPS inhibition of IL-12 production has been reported following ligation of macrophage Fcc, complement, or scavenger receptors [46] . The inhibitory effect observed was not dependent on particle internalization. Other studies reported that complement C1q regulates LPS-induced cytokine production in bmDCs and that iC3b is responsible for the induction of IL-10 and the downregulation of IL-12 in monocytes and DCs [47] [48] [49] . Receptor-mediated inhibition of IL-12 production may be exploited by pathogens to suppress or delay cell-mediated immunity development. Serum factors and receptors involved in modulation of IL-12/IL-10 production after bmDC stimulation with opsonized S. suis remain to be characterized. Experiments with heat-inactivated serum showed only a partial role of complement factors in IL-10 upregulation when S. suis is impaired for CW modifications or suilysin production. The role of complement in IL-12 downregulation could not be clearly demonstrated, and thus other serum factors might also be involved. This is certainly the case for wild-type S. suis, which is highly resistant to complement deposition. Moreover, IL-10 itself might contribute to the observed downregulation of IL-12 production. A slight tendency toward a reduction of costimulatory molecule expression was also repeatedly observed with bmDCs stimulated with serum opsonized strains. This tendency could also be the result of increased IL-10 production. For instance, a previous study showed that IL-10 induces the intracellular sequestration of MHC-II molecules [50] .
To conclude, our results show for the first time that S. suis activates bmDCs and suggest that these cells might play a role in host innate and adaptive immunity during infection. However, S. suis possesses different virulence factors that modulate these interactions. Based on our results, a model of S. suis interactions with DCs is proposed ( Figure 6 ). The CPS acts as a physical barrier that protects bacteria from phagocytosis and reduces cytokine production levels. CW modifications of PG and LTA and suilysin further protect S. suis from complement-mediated clearance. Overall, this results in low bacterial uptake, which might translate into reduced antigen processing and presentation to T cells. DC activation is additionally modulated by S. suis ligation to serum factors, which in turn reduces IL-12 production. We are presently evaluating the consequences of S. suis modulation of DC functions on the development of adaptive immune responses toward this pathogen.
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